Current Report Filing (8-k)
07 March 2017 - 8:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
March 6, 2017
LIPOCINE INC.
(Exact name of registrant as specified in
its charter)
Commission File No. 001-36357
Delaware
|
|
99-0370688
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification Number)
|
|
|
|
675 Arapeen Drive, Suite 202
Salt Lake City, Utah 84108
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number, including
area code:
(801) 994-7383
Former name or former address, if changed
since last report:
Not Applicable
______________________
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
As reported in its Annual Report on Form
10-K filed on the date hereof, on March 6, 2017, Lipocine Inc. (the “Company”) entered into a Controlled Equity Offering
SM
Sales Agreement, dated March 6, 2017 (the “Sales Agreement”), with Cantor Fitzgerald & Co., as agent (“Cantor
Fitzgerald”), pursuant to which the Company may issue and sell shares of its common stock, $0.0001 par value per share, having
an aggregate offering price of up to $20.0 million (the “Shares”) from time to time through Cantor Fitzgerald (the
“Offering”). The material terms of the Sales Agreement are described in the Company’s Annual Report on Form 10-K
filed on the date hereof. Also on March 6, 2017, the Company filed a prospectus supplement with the Securities and Exchange Commission
in connection with the Offering (the “Prospectus Supplement”) under its existing Registration Statement on Form S-3
(File No 333-199093), which became effective on October 14, 2014 (the “Registration Statement”).
Dorsey & Whitney LLP, counsel to the
Company, has issued a legal opinion relating to the Shares. A copy of such legal opinion, including the consent included therein,
is attached as Exhibit 5.1 hereto.
The Shares will be sold pursuant to the
Registration Statement, and offerings of the Shares will be made only by means of the Prospectus Supplement. This Current Report
on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities law of such state or jurisdiction.
|
Item 9.01
|
Financial Statements and Exhibits.
|
See Exhibit
Index attached hereto.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
LIPOCINE INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
|
March 6, 2017
|
|
By:
|
/s/ Mahesh V. Patel
|
|
|
|
|
|
Mahesh V. Patel
|
|
|
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
|
EXHIBIT INDEX
Exhibit Number
|
Description
|
5.1
|
Opinion of Dorsey & Whitney LLP, dated March 6, 2017
|
23.1
|
Consent of Dorsey & Whitney LLP (contained in Exhibit 5.1 above).
|
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2024 to May 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From May 2023 to May 2024